

STIMULAN®

POWER TO TRANSFORM OUTCOMES

CASE STUDY

Courtesy of Mr Rajesh Jogia

Consultant Podiatric Surgeon, University Hospitals of Leicester, UK

Clinical particulars

67-year-old male with Type 2 diabetes and BMI of 37 presented with osteomyelitis and interphalangeal joint destruction to his left hallux. This failed to resolve with conservative treatment regime of oral antibiotics and off-loading. Surgical management was to amputate the left hallux, however there was a risk of re-ulceration as he was already receiving treatment for Charcot arthropathy to his right foot.

Treatment

As a last effort to prevent amputation, surgical debridement was carried out, the bone was fenestrated and **STIMULAN** mixed with vancomycin and gentamicin used to fill the cavities. Surgery was carried out as a day case under local anaesthetic.

Outcome

2 weeks' post-operatively, the toe reduced in size. At the 16-month x-ray **STIMULAN** was seen to be completely absorbed, the patient was infection free and amputation had been avoided.



Presentation



Post-operative



2 weeks



16 months

For indications, contraindications, warnings and precautions see Instructions for Use. The treating physician is responsible for deciding the type and quantity of antibiotic used. Concurrent use of locally administered antibiotics may affect setting time. The mixing of antibiotics with the STIMULAN Kit/ STIMULAN Rapid Cure device is considered off-label usage of the medicinal product. To do so is at the professional risk of the surgeon / healthcare professional. This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/ approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2017, Biocomposites and STIMULAN are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorized copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710 / Patents pending: GB1502655.2, EP 16154210.5, US 15/040075, CN 201610089710.5, US 15/288328.

MA0026R2. Canada only. Not for distribution in the USA.